
Opinion|Videos|July 10, 2024
Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients
Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- In the monarchE and NATALEE trials, the endocrine therapy allowed was different. How did the type of endocrine therapy used impact toxicities seen, and how has that translated to your practice when selecting endocrine therapies?
Advertisement
Related to this article

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.

Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.

Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5

